Mesalazine-associated interstitial nephritis
Open Access
- 1 March 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 12 (3) , 622-623
- https://doi.org/10.1093/ndt/12.3.622
Abstract
Background. When used for oral treatment of inflam- matory bowel disease, Asacol (a coated form of mesala- zine = 5-aminosalicylic acid) can cause interstitial nephritis. The spectrum of severity, frequency of occur- rence and the best renal function test to detect this complication are not known. The value of immunosup- pression in addition to drug withdrawal is similarly undetermined. Methods. Four cases of interstitial nephritis which occurred in association with oral Asacol treatment are presented and a further 12 cases who received similar treatment are reviewed. Clinical trials published previ- ously were scrutinized to assess the frequency of impaired renal function. Results. The available evidence suggests that renal impairment of any severity may occur in up to 1 in 100 patients, but that clinically significant interstitial nephritis occurs in less than 1 in 500 patients. This is most reliably detected by an elevated serum creatinine concentration. If the diagnosis of nephrotoxicity is delayed until 18 months after commencement of med- ication, restoration of renal function, which is seen on withdrawal of medication alone up to 10 months, does not occur and there is no evidence to date to indicate that addition of immunosuppression confers any signi- ficant advantage at this later stage. Conclusions. It is suggested that serum creatinine con- centration should be measured each month for the first 3 months of treatment, 3-monthly for the remainder of the first year and annually thereafter. The use of concurrent immunosuppressive therapy may necessit- ate extension to the period of intensive monitoring. Any elevation of serum creatinine which cannot be related to a relapse of inflammatory bowel disease should prompt immediate withdrawal of Asacol and related medications and substitution of alternative therapy. Neither the lack of urinary abnormalities on routine testing nor the absence of clinical or laboratory features of drug allergy can be relied upon to rule outKeywords
This publication has 0 references indexed in Scilit: